Business Context and Reporting Period
This Form 8-K is filed by PowerUp Acquisition Corp. (not Aspire Biopharma Holdings, Inc.) on July 19, 2024. The registrant is a Cayman Islands-based special purpose acquisition company (SPAC) and an emerging growth company. The filing reports the termination of a material definitive agreement regarding a proposed business combination.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. As a SPAC in the process of terminating a merger, this report focuses on corporate events rather than operational financial performance.
Material Changes
- Termination of Merger Agreement: On July 19, 2024, PowerUp Acquisition Corp. delivered written notice to Visiox Pharmaceuticals, Inc. terminating the Agreement and Plan of Merger.
- Reason for Termination: The transaction was abandoned primarily because the conditions to closing set forth in Article VI of the Merger Agreement were not satisfied or waived by the deadline of June 30, 2024.
- Future Strategy: The Company intends to continue evaluating other possible business combination targets, though no assurance is given that these efforts will result in a transaction.
Guidance, Outlook, and Risks
Outlook: Management stated an intention to seek alternative business combination targets. However, the filing explicitly notes there can be no assurance that these evaluations will result in a successful transaction.
Risks and Contingencies: The primary risk highlighted is the failure to close the Visiox merger due to unmet conditions. The termination triggers the effects set forth in the original Merger Agreement, which may include the return of trust funds to shareholders or other contractual obligations, though specific financial consequences are not detailed in this text.
Investor Verification Checklist
- Verify the status of the Company's trust account and the potential return of funds to shareholders following the merger termination.
- Confirm the remaining timeline for the Company to complete a business combination before mandatory liquidation.
- Review the specific terms of the terminated Merger Agreement to understand any break-up fees or liabilities incurred.
- Monitor subsequent filings for announcements regarding new potential merger targets.